Table 4 Patients’ characteristics according to the presence or absence of silent myocardial ischemia or silent coronary artery disease in patients with LDL <3.35 mmol/L
|  | No SMI n = 788 | SMI n = 292 | Odds ratioa [95CI] | p | No CAD n = 909 | CAD n = 91 | Odds ratiob [95CI] | p |
|---|---|---|---|---|---|---|---|---|
Clinical characteristics | ||||||||
 Age, years | 61.6 ± 9.2 | 61.5 ± 8.6 |  | 0.90 | 61.4 ± 9.0 | 61.5 ± 8.7 |  | 0.93 |
 Gender, male/female | 405/383 | 209/83 | 2.4 [1.8–3.2] | <0.0001 | 486/423 | 73/18 | 3.5 [2.1–6.0] | <0.0001 |
 Body mass index, kg/m2 | 30.6 ± 6.2 | 29.1 ± 5.1 |  | <0.0001 | 30.5 ± 6.1 | 28.4 ± 4.4 |  | <0.01 |
Diabetes | ||||||||
 Diabetes duration, years | 13.8 ± 8.5 | 13.5 ± 8.6 |  | 0.56 | 13.8 ± 8.4 | 13.0 ± 8.5 |  | 0.39 |
 HbA1c, % | 8.4 ± 1.8 | 8.5 ± 2.0 |  | 0.43 | 8.5 ± 1.8 | 8.5 ± 2.1 |  | 0.95 |
 HbA1c, mmol/mol | 64 ± 6 | 65 ± 6 |  | 0.43 | 66 ± 6 | 65 ± 6 |  | 0.95 |
 Retinopathy, % | 243 (31.9) | 114 (40.4) | 1.4 [1.1–1.9] | 0.01 | 290 (33.0) | 41 (46.6) | 1.8 [1.1–2.8] | <0.05 |
 Nephropathy, % | 294 (57.6) | 112 (56.3) |  | 0.74 | 340 (56.2) | 36 (56.3) |  | 0.99 |
 Microalbuminuria >30 mg/day, % | 205 (30.3) | 88 (35.1) |  | 0.17 | 242 (30.9) | 35 (43.2) | 1.7 [1.1–2.7] | <0.05 |
 Peripheral arterial occlusive disease, % | 60 (7.9) | 59 (20.6) | 3.0 [2.1–4.5] | <0.0001 | 75 (8.5) | 23 (25.8) | 3.8 [2.2–6.4] | <0.0001 |
Additional cardiovascular risk factors | ||||||||
 Hypertension, % | 248 (74.3) | 154 (79.8) |  | 0.15 | 331 (75.2) | 60 (81.1) |  | 0.27 |
  Mean blood pressure, mmHg | 92 ± 11 | 94 ± 13 |  | <0.01 | 92 ± 12 | 97 ± 13 |  | <0.0001 |
 Atherogenic dyslipidemia, % | 36 (4.6) | 24 (8.2) | 1.9 [1.1–3.2] | <0.05 | 278 (61.6) | 57 (75.0) | 1.9 [1.1–3.2] | <0.05 |
 Lipid parameters | ||||||||
  HDL cholesterol, mmol/L | 1.3 ± 0.5 | 1.2 ± 0.4 |  | <0.01 | 1.3 ± 0.5 | 1.1 ± 0.4 |  | <0.0001 |
  Triglycerides, mmol/L | 1.7 ± 1.0 | 1.7 ± 0.9 |  | 0.48 | 1.7 ± 1.0 | 1.9 ± 1.1 |  | <0.01 |
  LDL cholesterol, mmol/L | 2.4 ± 0.6 | 2.4 ± 0.6 |  | 0.97 | 2.4 ± 0.6 | 2.5 ± 0.6 |  | 0.34 |
  Non HDL cholesterol, mmol/L | 3.2 ± 0.7 | 3.2 ± 0.7 |  | 0.637 | 3.2 ± 0.7 | 3.3 ± 0.7 |  | 0.05 |
  Apoprotein A1, g/L | 1.47 ± 0.29 | 1.47 ± 0.25 |  | 0.958 | 1.48 ± 0.29 | 1.39 ± 0.22 |  | 0.195 |
  Apoprotein B, g/L | 0.89 ± 0.19 | 0.92 ± 0.18 |  | 0.205 | 0.89 ± 0.19 | 1.03 ± 0.15 |  | 0.002 |
 Fibrate treatment, % | 67 (8.7) | 29 (10.2) |  | 0.45 | 76 (8.5) | 11 (12.2) |  | 0.24 |
 Statin treatment, % | 316 (40.9) | 122 (42.8) |  | 0.57 | 365 (41.0) | 39 (43.3) |  | 0.66 |
 Smoking, % | 163 (20.8) | 82 (28.3) | 1.5 [1.1–2.0] | 0.01 | 196 (21.7) | 32 (35.2) | 2.0 [1.2–3.1] | <0.01 |